Literature DB >> 24648314

Lung tumourigenesis in a conditional Cul4A transgenic mouse model.

Yi-Lin Yang1, Ming-Szu Hung, Yang Wang, Jian Ni, Jian-Hua Mao, David Hsieh, Alfred Au, Atul Kumar, David Quigley, Li Tai Fang, Che-Chung Yeh, Zhidong Xu, David M Jablons, Liang You.   

Abstract

Cullin4A (Cul4A) is a scaffold protein that assembles cullin-RING ubiquitin ligase (E3) complexes and regulates many cellular events, including cell survival, development, growth and cell cycle control. Our previous study suggested that Cul4A is oncogenic in vitro, but its oncogenic role in vivo has not been studied. Here, we used a Cul4A transgenic mouse model to study the potential oncogenic role of Cul4A in lung tumour development. After Cul4A over-expression was induced in the lungs for 32 weeks, atypical epithelial cells were observed. After 40 weeks, lung tumours were visible and were characterized as grade I or II adenocarcinomas. Immunohistochemistry (IHC) revealed decreased levels of Cul4A-associated proteins p21(CIP1) and tumour suppressor p19(ARF) in the lung tumours, suggesting that Cul4A regulated their expression in these tumours. Increased levels of p27(KIP1) and p16(INK4a) were also detected in these tumours. Moreover, the protein level of DNA replication licensing factor CDT1 was decreased. Genomic instability in the lung tumours was further analysed by the results from pericentrin protein expression and array comparative genomic hybridization analysis. Furthermore, knocking down Cul4A expression in lung cancer H2170 cells increased their sensitivity to the chemotherapy drug cisplatin in vitro, suggesting that Cul4A over-expression is associated with cisplatin resistance in the cancer cells. Our findings indicate that Cul4A is oncogenic in vivo, and this Cul4A mouse model is a tool in understanding the mechanisms of Cul4A in human cancers and for testing experimental therapies targeting Cul4A.
Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Ad-Cre; Cul4A; cell cycle; non-small cell lung cancer; transgenic mouse models

Mesh:

Substances:

Year:  2014        PMID: 24648314      PMCID: PMC4084828          DOI: 10.1002/path.4352

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  40 in total

1.  Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint.

Authors:  Leigh Ann A Higa; Ivailo S Mihaylov; Damon P Banks; Jianyu Zheng; Hui Zhang
Journal:  Nat Cell Biol       Date:  2003-10-26       Impact factor: 28.824

Review 2.  First-line chemotherapy for NSCLC: an overview of relevant trials.

Authors:  Chandra P Belani; Corey Langer
Journal:  Lung Cancer       Date:  2002-12       Impact factor: 5.705

3.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.

Authors:  P L Porter; K E Malone; P J Heagerty; G M Alexander; L A Gatti; E J Firpo; J R Daling; J M Roberts
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

5.  Tumor susceptibility of p21(Waf1/Cip1)-deficient mice.

Authors:  J Martín-Caballero; J M Flores; P García-Palencia; M Serrano
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

6.  TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Authors:  Kohichiroh Yasui; Shigeki Arii; Chen Zhao; Issei Imoto; Masakazu Ueda; Hisaki Nagai; Mitsuru Emi; Johji Inazawa
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

7.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

8.  Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage.

Authors:  Jian Hu; Chad M McCall; Tomohiko Ohta; Yue Xiong
Journal:  Nat Cell Biol       Date:  2004-09-26       Impact factor: 28.824

9.  Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice.

Authors:  Jeannette Philipp-Staheli; Kyung-Hoon Kim; Shannon R Payne; Kay E Gurley; Denny Liggitt; Gary Longton; Christopher J Kemp
Journal:  Cancer Cell       Date:  2002-05       Impact factor: 31.743

10.  Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.

Authors:  Steffan T Nawrocki; Kevin R Kelly; Peter G Smith; Claudia M Espitia; Anthony Possemato; Sean A Beausoleil; Michael Milhollen; Stephen Blakemore; Michael Thomas; Allison Berger; Jennifer S Carew
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531

View more
  12 in total

Review 1.  Distinct and overlapping functions of the cullin E3 ligase scaffolding proteins CUL4A and CUL4B.

Authors:  Jeffrey Hannah; Pengbo Zhou
Journal:  Gene       Date:  2015-09-03       Impact factor: 3.688

2.  CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.

Authors:  Yunshan Wang; Pengju Zhang; Ziming Liu; Qin Wang; Mingxin Wen; Yuli Wang; Hongtu Yuan; Jian-Hua Mao; Guangwei Wei
Journal:  Mol Cancer       Date:  2014-11-21       Impact factor: 27.401

3.  Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells.

Authors:  Ming-Szu Hung; I-Chuan Chen; Liang You; David M Jablons; Ya-Chin Li; Jian-Hua Mao; Zhidong Xu; Jr-Hau Lung; Cheng-Ta Yang; Shih-Tung Liu
Journal:  J Cell Mol Med       Date:  2016-03-10       Impact factor: 5.310

4.  Integrative analysis of multi-omics data reveals distinct impacts of DDB1-CUL4 associated factors in human lung adenocarcinomas.

Authors:  Hong Yan; Lei Bi; Yunshan Wang; Xia Zhang; Zhibo Hou; Qian Wang; Antoine M Snijders; Jian-Hua Mao
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

5.  Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.

Authors:  B Englinger; M Mair; W Miklos; C Pirker; T Mohr; S van Schoonhoven; D Lötsch; W Körner; F Ferk; S Knasmüller; P Heffeter; B K Keppler; M Grusch; W Berger
Journal:  Br J Cancer       Date:  2017-01-17       Impact factor: 7.640

Review 6.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

7.  CUL4high Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival.

Authors:  Yannan Wang; Fan Yan; Abu Nasar; Zhe-Sheng Chen; Nasser Khaled Altorki; Brendon Stiles; Navneet Narula; Pengbo Zhou
Journal:  Am J Pathol       Date:  2021-06-11       Impact factor: 5.770

8.  Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.

Authors:  Yi-Lin Yang; Jian Ni; Ping-Chih Hsu; Jian-Hua Mao; David Hsieh; Angela Xu; Geraldine Chan; Alfred Au; Zhidong Xu; David M Jablons; Liang You
Journal:  J Cell Mol Med       Date:  2015-07-27       Impact factor: 5.310

9.  Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway.

Authors:  Jun Deng; Wan Lei; Xiaojun Xiang; Ling Zhang; Jun Lei; Yu Gong; Meijiao Song; Yi Wang; Ziling Fang; Feng Yu; Miao Feng; Ze Sun; Jun Chen; Zhengyu Zhan; Jianping Xiong
Journal:  Oncotarget       Date:  2016-03-01

10.  Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro.

Authors:  Ada W Y Leung; Stacy S Hung; Ian Backstrom; Daniel Ricaurte; Brian Kwok; Steven Poon; Steven McKinney; Romulo Segovia; Jenna Rawji; Mohammed A Qadir; Samuel Aparicio; Peter C Stirling; Christian Steidl; Marcel B Bally
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.